View in EDS

Role of short chain fatty acids on astrocytes and microglia in Alzheimer's disease brain.

Saved in:
Bibliographic Details
Title: Role of short chain fatty acids on astrocytes and microglia in Alzheimer's disease brain.
Authors: Senarath, Rathnayaka Mudiyanselage Uththara Sachinthanie1,2 (AUTHOR), Burton, Matthew1 (AUTHOR), Fernando, Welisarage Mary Kendrea Thiasangee3 (AUTHOR), Jayasena, Vijay4 (AUTHOR), Brennan, Charles5 (AUTHOR), Fernando, Wanakulasuriya Mary Ann Dipika Binosha1,2 (AUTHOR) w.fernando@ecu.edu.au
Source: International Journal of Food Science & Technology. Sep2024, Vol. 59 Issue 9, p5902-5911. 10p.
Subjects: Short-chain fatty acids, Alzheimer's disease, Immunoregulation, Neurodegeneration, Fatty acids
Abstract: Summary: Short‐chain fatty acids (SCFAs) hold exert many nutritional benefits on both physiological and pathological processes, including host metabolism, immune modulation, and appetite control. Originating from the microbial fermentation of resistant starches and dietary fibre in the colon, SCFAs have the capability to traverse the blood–brain barrier (BBB). It is evident that SCFAs play a critical role in the development of neurodegenerative disorders such as Alzheimer's disease (AD). AD is the most common form of dementia and is characterised by the deposition of amyloid β peptides (Aβ) and tau hyperphosphorylation. SCFAs have demonstrated the potential to interfere with the protein–protein interactions required for Aβ peptides to form neurotoxic oligomers. Moreover, research indicates that the SCFAs ability to maintain endothelial integrity and interact with neuroglial cells through the BBB may assist in downregulating excessive neuroinflammatory responses to amyloid peptides. This review summarises the research on SCFAs' potential role in AD and understand their mechanism of actions on astrocytes and microglia. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Food Science & Technology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Summary: Short‐chain fatty acids (SCFAs) hold exert many nutritional benefits on both physiological and pathological processes, including host metabolism, immune modulation, and appetite control. Originating from the microbial fermentation of resistant starches and dietary fibre in the colon, SCFAs have the capability to traverse the blood–brain barrier (BBB). It is evident that SCFAs play a critical role in the development of neurodegenerative disorders such as Alzheimer's disease (AD). AD is the most common form of dementia and is characterised by the deposition of amyloid β peptides (Aβ) and tau hyperphosphorylation. SCFAs have demonstrated the potential to interfere with the protein–protein interactions required for Aβ peptides to form neurotoxic oligomers. Moreover, research indicates that the SCFAs ability to maintain endothelial integrity and interact with neuroglial cells through the BBB may assist in downregulating excessive neuroinflammatory responses to amyloid peptides. This review summarises the research on SCFAs' potential role in AD and understand their mechanism of actions on astrocytes and microglia. [ABSTRACT FROM AUTHOR]
ISSN:09505423
DOI:10.1111/ijfs.17380